Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. on February 12, 2026. The filing details a material definitive agreement involving a private placement offering, a royalty purchase agreement, and changes to the Board of Directors. The company is a clinical-stage biopharmaceutical firm focused on its vidofludimus calcium program.
Key Financial Metrics and Transaction Details
- Private Placement Proceeds: The Company expects to raise approximately $200 million in aggregate gross proceeds from the issuance of Pre-Funded Warrants and Common Warrants.
- Offering Price: The purchase price for each Pre-Funded Warrant and accompanying Common Warrant is $0.873120.
- Exercise Prices: Pre-Funded Warrants are exercisable at $0.0001 per share. Common Warrants are exercisable at $0.873220 per share (subject to adjustment).
- Placement Agent Fees: The Company agreed to pay placement agents a fee equal to 6% of aggregate gross proceeds, payable upon issuance and upon cash exercise of Common Warrants.
- Use of Proceeds: Net proceeds are intended to fund clinical trials, operations, working capital, and general corporate purposes.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for a specific reporting period.
Material Changes and Agreements
Private Placement and Reverse Stock Split
The Company entered into a Securities Purchase Agreement to sell Pre-Funded Warrants and Common Warrants. The closing is expected on or about February 17, 2026. Concurrently, the Company will seek stockholder approval for a reverse stock split of its Common Stock at a ratio of not less than 10:1.
Royalty Purchase Agreement
The Company entered into a Royalty Purchase Agreement with certain Series B Warrant holders and BVF Partners, L.P. Under this agreement:
- 51,087,000 Series B Warrants will be exchanged for a pro rata share of an aggregate 5% synthetic royalty on future sales of the vidofludimus calcium program.
- Royalty payments are due quarterly following the first commercial sale.
- Upon closing, 35,579,667 Series B Warrants will remain outstanding.
Board of Directors Changes
- Appointment: Thor Nagel was appointed as a Class III Director.
- Appointment: Simona Skerjanec was appointed as Interim Chairperson of the Board.
- Resignation: Maria Törnsén resigned from the Board in connection with the Offering. The resignation was not due to any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the intended use of proceeds and the timing of the resale registration statement. The Company disclaims any obligation to update these statements.
Key Risks and Contingencies:
- Market Conditions: Risks associated with general market conditions and the Company's cash needs.
- Regulatory Approval: The reverse stock split is contingent upon stockholder approval.
- Registration: The resale registration statement (Form S-3 or S-1) must be filed within 45 days of the closing date and declared effective by the SEC.
- Unregistered Securities: The Warrants are being sold without registration under the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and sales to accredited investors.
Investor Verification Checklist
- Verify the final closing date of the Offering and the actual amount of gross proceeds raised.
- Confirm the outcome of the stockholder vote regarding the reverse stock split (minimum 10:1 ratio).
- Monitor the filing and effectiveness of the resale registration statement (Form S-3 or S-1) for the Warrants.
- Review the definitive terms of the 5% synthetic royalty agreement and the definition of "First Commercial Sale."
- Check for any subsequent filings regarding the resignation of Maria Törnsén or the appointment of Thor Nagel and Simona Skerjanec.